Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MethylGene prices IPO

Cancer and infectious disease company MethylGene (TSE:MYG) raised C$20 million ($14.8 million) in an

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE